-
Something wrong with this record ?
Current antiviral drugs and their analysis in biological materials - Part II: Antivirals against hepatitis and HIV viruses
L. Nováková, J. Pavlík, L. Chrenková, O. Martinec, L. Červený,
Language English Country England, Great Britain
Document type Journal Article, Review
- MeSH
- Antiviral Agents analysis pharmacology therapeutic use MeSH
- Biological Factors analysis metabolism MeSH
- Hepatitis drug therapy metabolism MeSH
- HIV Infections drug therapy metabolism MeSH
- HIV-1 drug effects metabolism MeSH
- Humans MeSH
- Animals MeSH
- Check Tag
- Humans MeSH
- Animals MeSH
- Publication type
- Journal Article MeSH
- Review MeSH
This review is a Part II of the series aiming to provide comprehensive overview of currently used antiviral drugs and to show modern approaches to their analysis. While in the Part I antivirals against herpes viruses and antivirals against respiratory viruses were addressed, this part concerns antivirals against hepatitis viruses (B and C) and human immunodeficiency virus (HIV). Many novel antivirals against hepatitis C virus (HCV) and HIV have been introduced into the clinical practice over the last decade. The recent broadening portfolio of these groups of antivirals is reflected in increasing number of developed analytical methods required to meet the needs of clinical terrain. Part II summarizes the mechanisms of action of antivirals against hepatitis B virus (HBV), HCV, and HIV, their use in clinical practice, and analytical methods for individual classes. It also provides expert opinion on state of art in the field of bioanalysis of these drugs. Analytical methods reflect novelty of these chemical structures and use by far the most current approaches, such as simple and high-throughput sample preparation and fast separation, often by means of UHPLC-MS/MS. Proper method validation based on requirements of bioanalytical guidelines is an inherent part of the developed methods.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc18024565
- 003
- CZ-PrNML
- 005
- 20180716123317.0
- 007
- ta
- 008
- 180709s2018 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.jpba.2017.07.003 $2 doi
- 035 __
- $a (PubMed)29031512
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Nováková, Lucie $u Department of Analytical Chemistry, Faculty of Pharmacy in Hradec Králové, Charles University, Akademika Heyrovského 1203, 500 05 Hradec Králové, Czech Republic. Electronic address: nol@email.cz.
- 245 10
- $a Current antiviral drugs and their analysis in biological materials - Part II: Antivirals against hepatitis and HIV viruses / $c L. Nováková, J. Pavlík, L. Chrenková, O. Martinec, L. Červený,
- 520 9_
- $a This review is a Part II of the series aiming to provide comprehensive overview of currently used antiviral drugs and to show modern approaches to their analysis. While in the Part I antivirals against herpes viruses and antivirals against respiratory viruses were addressed, this part concerns antivirals against hepatitis viruses (B and C) and human immunodeficiency virus (HIV). Many novel antivirals against hepatitis C virus (HCV) and HIV have been introduced into the clinical practice over the last decade. The recent broadening portfolio of these groups of antivirals is reflected in increasing number of developed analytical methods required to meet the needs of clinical terrain. Part II summarizes the mechanisms of action of antivirals against hepatitis B virus (HBV), HCV, and HIV, their use in clinical practice, and analytical methods for individual classes. It also provides expert opinion on state of art in the field of bioanalysis of these drugs. Analytical methods reflect novelty of these chemical structures and use by far the most current approaches, such as simple and high-throughput sample preparation and fast separation, often by means of UHPLC-MS/MS. Proper method validation based on requirements of bioanalytical guidelines is an inherent part of the developed methods.
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a antivirové látky $x analýza $x farmakologie $x terapeutické užití $7 D000998
- 650 _2
- $a biologické faktory $x analýza $x metabolismus $7 D001685
- 650 _2
- $a HIV infekce $x farmakoterapie $x metabolismus $7 D015658
- 650 _2
- $a HIV-1 $x účinky léků $x metabolismus $7 D015497
- 650 _2
- $a hepatitida $x farmakoterapie $x metabolismus $7 D006505
- 650 _2
- $a lidé $7 D006801
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a přehledy $7 D016454
- 700 1_
- $a Pavlík, Jakub $u Department of Analytical Chemistry, Faculty of Pharmacy in Hradec Králové, Charles University, Akademika Heyrovského 1203, 500 05 Hradec Králové, Czech Republic.
- 700 1_
- $a Chrenková, Lucia $u Department of Analytical Chemistry, Faculty of Pharmacy in Hradec Králové, Charles University, Akademika Heyrovského 1203, 500 05 Hradec Králové, Czech Republic.
- 700 1_
- $a Martinec, Ondřej $u Department of Pharmacology and Toxicology, Faculty of Pharmacy in Hradec Králové, Charles University, Akademika Heyrovského 1203, 500 05 Hradec Králové, Czech Republic.
- 700 1_
- $a Červený, Lukáš $u Department of Pharmacology and Toxicology, Faculty of Pharmacy in Hradec Králové, Charles University, Akademika Heyrovského 1203, 500 05 Hradec Králové, Czech Republic.
- 773 0_
- $w MED00002894 $t Journal of pharmaceutical and biomedical analysis $x 1873-264X $g Roč. 147, č. - (2018), s. 378-399
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/29031512 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20180709 $b ABA008
- 991 __
- $a 20180716123615 $b ABA008
- 999 __
- $a ok $b bmc $g 1316696 $s 1021486
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2018 $b 147 $c - $d 378-399 $e 20170708 $i 1873-264X $m Journal of pharmaceutical and biomedical analysis $n J Pharm Biomed Anal $x MED00002894
- LZP __
- $a Pubmed-20180709